Artelo Biosciences Inc. (ARTL:NASDAQ) will present scientific insights on ART26.12, its FABP5 (fatty acid binding protein 5) inhibitor, on April 3, 2025 at the 4th ACE Drug Discovery Summit in London, reported Jason Kolbert, D. Boral Capital analyst, in an April 2 research note.
"The upcoming presentation aims to shed light on the downstream biological effects of FABP5 inhibition, which could inform future therapeutic developments across multiple indications," wrote Kolbert.
598% Return Potential
D. Boral maintained its $6 per share price target on Artelo, now trading at about $0.86 per share. The difference between these prices implies a possible gain of 598%.
The biopharma remains a Buy.
Artelo's market cap is $3 million. Its 52-week range is $0.91–1.70 per share.
Data Due in Q2/25
Kolbert reported that at the upcoming ACE Drug Discovery Summit, Myles Osborn, Artelo's lead medicinal chemist, will present "Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications." Osborn will discuss the effects of FABP5 inhibition on various disease models and share new perspectives on this therapeutic target.
In preclinical models, Artelo's ART26.12 showed the potential to treat neuropathic pain, osteoarthritis, cancer and cancer-related bone pain, noted Kolbert. ART26.12 is currently in a Phase 1 single ascending dose study, the first ever clinical evaluation of a selective FABP5 inhibitor, Kolbert wrote. The trial is due to read out in Q2/25.
Updates on Pipeline
Kolbert commented on Artelo's other clinical programs. The lead, ART27.13, a benzimidazole derivative, is "a peripherally selective cannabinoid receptor agonist designed to stimulate appetite and maintain lean body mass without central nervous system-related side effects commonly associated with traditional cannabinoid therapies," the analyst described.
The biopharma is advancing ART27.13 through clinical trials for cancer-related anorexia and cachexia, a metabolic disorder from which patients suffer severe weight loss and muscle wasting, Kolbert relayed. The data generated so far suggest ART27.13 can stimulate appetite and stabilize weight in cachectic patients. Initial data from the Phase 2 part of the CAReS trial, evaluating ART27.13 as a treatment of cancer-related anorexia and weight loss, is expected by mid-2025.
"With no U.S. Food and Drug Administration-approved treatments currently available for cancer cachexia, ART27.13 represents a significant opportunity to address an unmet medical need," wrote Kolbert.
Artelo also is advancing ART12.11, a novel cocrystal of cannabidiol (CBD) and tetramethylpyrazine (TMP) targeting anxiety and depression, toward first-in-human trials.
"While these developments highlight Artelo's ability to execute on its clinical strategy," Kolbert pointed out, "financial headwinds may pose challenges in maintaining momentum."
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
